Colon Pharmaceutical announced that due to the implementation of the 2026 mid-term dividend adjustment, the upper limit of the company's share repurchase price was adjusted from no more than 34.53 yuan/share to no more than 34.41 yuan/share. The adjusted upper limit will take effect from October 21, 2026. The reason for the adjustment was a cash dividend of 1.26 yuan for every 10 shares. The company previously planned to use its own capital to repurchase A-shares through centralized bidding, with a total repurchase capital of not less than 50 million yuan and no more than 100 million yuan. As of the date of this announcement, 350,000 shares had been repurchased, accounting for 0.02% of the total share capital. The highest transaction price was 29.7 yuan/share, the lowest price was 29.55 yuan/share, and the transaction amount was 10.366 million yuan. According to the adjusted upper limit, it is estimated that approximately 1.4531 million shares and 2,961 million shares can be repurchased in accordance with the lower and upper repurchase amounts.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.